清脂化浊膏联合达格列净治疗2型糖尿病合并非酒精性脂肪性肝病
Observation on the therapeutic effect of Qingzhi Huazhuo ointment combined with dapagliflozin in the treatment of T2DM complicated with NAFLD
目的 探讨清脂化浊膏联合达格列净治疗2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)的临床疗效,及其对患者糖脂代谢、肝功能及炎症指标的影响。 方法 回顾性纳入本院收治的T2DM合并NAFLD患者80例,依据实际治疗方案分为对照组和研究组。对照组予达格列净治疗,研究组在对照组基础上加用清脂化浊膏。比较2组临床总有效率、中医证候积分、糖脂代谢指标、肝功能指标及血清学指标。 结果 研究组总有效率显著高于对照组(85.71% vs. 65.79%,P<0.05)。治疗后,研究组脂联素(APN)水平高于对照组(P<0.05);空腹血糖(FPG)、餐后2小时血糖(2 h PG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、丙氨酸转氨酶(ALT)、白细胞介素-1β(IL-1β)、消皮素D(GSDMD)、半胱氨酸天冬氨酸蛋白酶-1(Caspase-1)水平及中医证候积分均低于对照组(P<0.05)。 结论 清脂化浊膏联合达格列净可有效改善T2DM合并NAFLD患者的糖脂代谢及肝功能,减轻炎症反应,提高临床疗效。
Objective To explore the therapeutic effect of Qingzhi Huazhuo ointment plus dapagliflozin on type 2 diabetes mellitus (T2DM) complicated with nonalcoholic fatty liver disease (NAFLD), as well as its influences on glucose and lipid metabolism, liver function and inflammatory indexes. Methods A retrospective study was conducted on 80 patients with T2DM complicated with NAFLD admitted to our hospital. The subjects were divided into a control group and a research group according to their different treatment methods. The control group adopted dapagliflozin, while the research group adopted Qingzhi Huazhuo ointment on the basis of that. The two groups were compared in terms of total effective rate, TCM syndrome scores, glucose and lipid metabolism indicators, liver function indicators, and serological indicators. Results The research group had a significantly higher total effective rate (85.71%) than the control group (65.79%) (P<0.05). After treatment, the level of adiponectin (APN) was higher in the research group than that in the control group (P<0.05), while the levels of fasting blood glucose (FPG), 2-hour postprandial blood glucose (2hPG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), interleukin-1 β (IL-1 β), gasdermin D (GSDMD), cysteine aspartate protease-1 (Caspase-1), and the TCM syndrome scores were all lower than those in the control group (P<0.05). Conclusion The joint intervention of Qingzhi Huazhuo ointment and dapagliflozin in patients with T2DM complicated with NAFLD can effectively improve glucose and lipid metabolism and liver function, reduce inflammatory reactions, and improve clinical efficacy.
| [1] |
戚玉琴, 杨浩, 盖显英. 司美格鲁肽联合二甲双胍恩格列净治疗2型糖尿病合并非酒精性脂肪性肝病患者疗效及安全分析[J]. 糖尿病新世界, 2024, 27(2):12-15. |
| [2] |
吕春卉, 李大炜, 王小洁, |
| [3] |
范国洽, 曹柳, 刘珊. 玉泉胶囊对2型糖尿病合并非酒精性脂肪性肝病患者糖脂代谢功能的影响[J]. 中国药业, 2025, 34(1):86-89. |
| [4] |
|
| [5] |
李粮, 赵凡, 赵海桃, |
| [6] |
孟祥雨, 白立炜, 尹清风, |
| [7] |
王诗淞, 林辉雄, 张泰胜, |
| [8] |
|
| [9] |
王露露, 祁海燕, 王高雷, |
| [10] |
吴小梅, 李开楊, 王高琼, |
| [11] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4):315-409. |
| [12] |
中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病的诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 18(3):163-166. |
| [13] |
张声生,李军祥. 非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J]. 中医杂志, 2017, 58(19):1706-1710. |
| [14] |
国家中医药管理局. 中医病证诊断疗效标准[M]. 南京: 南京大学出版社, 1994. |
| [15] |
孙妍, 王露. 卡格列净联合二甲双胍对2型糖尿病合并非酒精性脂肪肝患者血尿酸及胰岛素抵抗的影响[J]. 中国医学创新, 2021, 18(30):121-124. |
| [16] |
安盟盟, 刘建凤, 李辉, |
| [17] |
秦国鼎, 裴赵伟, 朱红梅. 恩格列净联合熊去氧胆酸对2型糖尿病合并非酒精性脂肪性肝病患者胰岛素抵抗、肝功能以及肝纤维化的影响[J]. 中国医院用药评价与分析, 2024, 24(3):291-294. |
| [18] |
孙峥, 王笑烨, 袁景, |
| [19] |
郭伟, 刘娜. 达格列净联合二甲双胍对2型糖尿病合并非酒精性脂肪性肝病患者肝脂肪变性的影响[J]. 华中科技大学学报(医学版), 2023, 52(4):530-534. |
| [20] |
潘娟, 王琪, 张燕. 达格列净联合二甲双胍治疗2型糖尿病合并非酒精性脂肪性肝病的疗效及安全性观察[J]. 贵州医药, 2023, 47(3):406-407. |
| [21] |
李海玲, 董陆玲, 杨亚萍, |
| [22] |
马静, 祁月英, 张忠勇, |
| [23] |
关婕婷, 张秋香, 陈红艳, |
| [24] |
陈敏灵, 杨柳清, 李亮, |
| [25] |
张媛媛, 倪英群, 张进军, |
无锡市中医药管理局科技项目(ZYYB30)
/
| 〈 |
|
〉 |